The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11148 malaria professionals are enjoying the free benefits of MalariaWorld today


Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters

October 30, 2021 - 13:10 -- Open Access
Popovici J, Tebben K, Witkowski B, Serre D
Int J Parasitol Drugs Drug Resist. 2021 Apr;15:36-42

Plasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients.

Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil

August 17, 2021 - 15:52 -- Open Access
Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, Soares Moura A, Advani N, Kahn M, Pal S, Gerth-Guyette E, Bansil P, Domingo GJ, Pereira D, Lacerda MV
PLoS Negl Trop Dis. 2021 Aug 12;15(8):e0009649

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzyme deficiency, prevalent in many malaria-endemic countries. G6PD-deficient individuals are susceptible to hemolysis during oxidative stress, which can occur from exposure to certain medications, including 8-aminoquinolines used to treat Plasmodium vivax malaria. Accordingly, access to point-of-care (POC) G6PD testing in Brazil is critical for safe treatment of P. vivax malaria.

Anti‐malarial drug effects on parasite dynamics in vivax malaria

March 24, 2021 - 14:41 -- Open Access
Nicholas J. White
Malaria Journal 2021 20:161, 21 March 2021

Relapses of Plasmodium vivax malaria are prevented by 8-aminoquinolines. If hypnozoites survive, then the subsequent blood stage infections in early relapses (< 2 months) are suppressed by the slowly eliminated anti-malarial drugs used to treat the blood stage infection (chloroquine, artemisinin combination treatments), but they are not usually eliminated.

Subscribe to RSS - 8-aminoquinolines